Table 1 Characteristics of Randomized Clinical Trials (RCTs)
From: Effect of cannabinoids on glutamate levels in the human brain: a systematic review and meta-analysis
Article | Study Design | Intervention | Dose | Population | Sample Size | Duration of Treatment (Tx) | Frequency of Tx | Delivery of Tx |
|---|---|---|---|---|---|---|---|---|
Bloomfield et al. 2021 | COT | THC cap | 15 mg | Healthy volunteers (mean age:23.5) | 40 | 1 day | once | po |
Colizzi et al. 2020 | COT | THC IV | 1.19 mg | Healthy volunteers (mean age: 24.4) | 32 | 1 day | once | IV |
Davies et al. 2023 | RCT | CBD cap | 600 mg | Clinical high risk for psychosis patients | 28 | 1 day | once | po |
Mason et al. 2019 | COT | THC vapor | 300ug/kg | Occasional cannabis users (mean age: 21.8) | 40 | 1 day | One full dose or divided in 3 successive doses | Inh |
O’neill et al. 2021 | COT | CBD cap | 600 mg | Psychotic patients (mean age: 27.73) | 30 | 1 day | once | po |
Pretzsch et al. 2019a | COT | CBD liq | 600 mg | ASD patients (mean ag 29.99) | 34 | 1 day | once | po |
Pretzsch et al. 2019b | COT | CBDV liq | 600 mg | ASD patients (mean age: 29.88) | 34 | 1 day | once | po |
Solowij et al. 2015 | COT | THC vapor | 6 mg | Human Volunteers (mean age: 21.3) | 30 | 1 day | once | Inh |
CBD vapor | 200 mg | |||||||
Van boxel et al. 2023 | RCT | CBD cap | 600 mg | Recent -onset Schizophrenic patients | 30 | 28 days | daily | po |